Table 2. The clinical characteristics and treatment modalities of patients with NK/T-cell lymphoma.
| Parametersa | Total n (%) | AGR < 1.3 n (%) | AGR ≥ 1.3 n (%) | P value |
|---|---|---|---|---|
| Overall | 331 (100) | 117 (100) | 214 (100) | |
| Male gender | 227 (68.6) | 75 (64.1) | 152 (71.0) | 0.194 |
| Age (years) | 42 (11–80) | 44 (11–77) | 41 (13–80) | 0.069 |
| Age > 60 years | 51 (15.4) | 24 (20.5) | 27 (12.6) | 0.057 |
| BMI (kg/m2) | 21.2 (13.7–44.0) | 20.4 (13.7–44.0) | 21.4 (14.8–44.0) | 0.010 |
| BMI < 18.5 kg/m2 | 53 (16.0) | 26 (22.2) | 27 (12.6) | 0.023 |
| ECOG score ≥ 2 | 52 (15.7) | 33 (28.2) | 19 (8.9) | 0.000 |
| Primary site | ||||
| UAT | 294 (88.8) | 98 (83.8) | 196 (91.6) | 0.031 |
| EUAT | 37 (11.2) | 19 (16.2) | 18 (8.4) | |
| Ann Arbor stage | ||||
| I–II | 269 (81.3) | 87 (74.4) | 182 (85.0) | 0.017 |
| III–IV | 62 (18.7) | 30 (25.6) | 32 (15.0) | |
| B symptoms | 173 (52.3) | 86 (73.5) | 87 (40.7) | 0.000 |
| Elevated LDH | 96 (29.0) | 47 (40.2) | 49 (22.9) | 0.001 |
| Involvement of regional lymph nodes | 119 (36.0) | 58 (49.6) | 61 (28.5) | 0.000 |
| Extranodal sites ≥ 2 | 44 (13.3) | 21 (17.9) | 23 (10.7) | 0.065 |
| IPI score | ||||
| Low risk (0–1) | 259 (78.2) | 61 (69.2) | 178 (83.2) | 0.000 |
| Intermediate risk (2–3) | 50 (15.1) | 20 (17.1) | 30 (14.0) | |
| High risk (4–5) | 22 (6.6) | 16 (13.7) | 6 (2.8) | |
| NKPI score | ||||
| Low risk(0) | 101 (30.5) | 12 (10.3) | 89 (41.6) | 0.000 |
| Intermediate risk(1–2) | 167 (50.5) | 68 (58.1) | 99 (46.3) | |
| High risk (3–4) | 63 (19.0) | 37 (31.6) | 26 (12.1) | |
| Total protein (g/L) | 72.1 (32.5–89.2) | 72.2 (32.5–89.2) | 72.0 (41.5–85.7) | 0.450 |
| Serum albumin (g/L) | 41.5 (21.6–54.4) | 38.0 (21.6–45.6) | 43.5 (26.8–54.4) | 0.000 |
| Hypoalbuminemia (<35 g/L) | 38 (11.5) | 29 (24.8) | 9 (4.2) | 0.000 |
| WBC count (k/cc) | 5.9 (0.9–23.0) | 5.7 (1.6–15.6) | 6.0 (0.9–23.0) | 0.262 |
| Neutrophil count (k/cc) | 3.5 (0.4–20.1) | 3.3 (0.6–12.9) | 3.5 (0.4–20.1) | 0.644 |
| Lymphocyte count (k/cc) | 1.5 (0.2–5.4) | 1.4 (0.2–4.5) | 1.6 (0.3–5.4) | 0.032 |
| CRP (n = 246, mg/L) | 6.6 (0.2–154.9) | 12.8 (0.5–154.9) | 3.9 (0.2–87.6) | 0.000 |
| ESR (n = 117, mm/h) | 17 (1–110) | 41 (3–104) | 11 (1–110) | 0.000 |
| Serum creatinine (μmol/L) | 67.1 (31.6–116.0) | 64.1 (32.8–108.0) | 69.3 (31.6–116.0) | 0.011 |
| Treatment modalities | ||||
| Chemotherapy alone | 107 (32.3) | 51 (43.6) | 56 (26.2) | 0.001 |
| RT ± chemotherapy | 224 (67.7) | 66 (56.4) | 158 (73.8) | |
| Chemotherapeutic regimen | ||||
| Asparaginase–containing | 125 (39.3) | 55 (49.1) | 70 (34.0) | 0.008 |
| Anthracycline–based | 193 (60.7) | 57 (50.9) | 136 (66.0) | |
| Radiation dose (Gy) | 54.6 (18.0–74.0) | 54.6 (20.0–74.0) | 54.6 (18.0–64.0) | 0.166 |
| Chemotherapy cycles | 4 (0–10) | 4 (1–9) | 4 (0–10) | 0.933 |
Notes.
a
Continuous variables are presented as medians (range), and categorical variables are shown as frequencies and percentages.
- AGR
- albumin to globulin ration
- BMI
- body mass index
- CRP
- C-reactive protein
- ECOG
- Eastern Cooperative Oncology Group
- ESR
- erythrocyte sedimentation rate
- EUAT
- extra-upper aerodigestive tract
- IPI
- International Prognostic Index
- LDH
- lactate dehydrogenase
- NKPI
- natural killer/T-cell lymphoma prognostic index
- RT
- radiotherapy
- UAT
- upper aerodigestive tract
- WBC
- white blood cell